About Macrocure Ltd (NASDAQ:MCUR)
Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:MCUR
- CUSIP: N/A
- Web: www.macrocure.com
- 50 Day Moving Avg: $1.51
- 200 Day Moving Avg: $1.54
- 52 Week Range: $0.75 - $3.20
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.72
- P/E Growth: 0.00
- Return on Equity: -24.50%
- Return on Assets: -22.85%
- Average Volume: 40,588 shs.
- Beta: 0.62
Frequently Asked Questions for Macrocure Ltd (NASDAQ:MCUR)
What is Macrocure Ltd's stock symbol?
Macrocure Ltd trades on the NASDAQ under the ticker symbol "MCUR."
How were Macrocure Ltd's earnings last quarter?
Macrocure Ltd (NASDAQ:MCUR) announced its earnings results on Tuesday, November, 17th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. View Macrocure Ltd's Earnings History.
Who are some of Macrocure Ltd's key competitors?
Some companies that are related to Macrocure Ltd include AbbVie (ABBV), ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Repligen Corporation (RGEN), Aimmune Therapeutics (AIMT), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Check-Cap (CHEK), Advanced Accelerator Applications S.A. (AAAP), DARA Biosciences (DARA) and Salix Pharmaceuticals (SLXP).
How do I buy Macrocure Ltd stock?
Shares of Macrocure Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Macrocure Ltd's stock price today?
MarketBeat Community Rating for Macrocure Ltd (NASDAQ MCUR)MarketBeat's community ratings are surveys of what our community members think about Macrocure Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Macrocure Ltd stock can currently be purchased for approximately $1.51.
Consensus Ratings for Macrocure Ltd (NASDAQ:MCUR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Macrocure Ltd (NASDAQ:MCUR)
Analysts' Ratings History for Macrocure Ltd (NASDAQ:MCUR)
(Data available from 10/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/18/2016||Credit Suisse Group||Downgrade||Neutral -> Underperform||$1.00||N/A|
|10/28/2015||Jefferies Group LLC||Lower Price Target||Hold||$1.50||N/A|
Earnings History for Macrocure Ltd (NASDAQ:MCUR)Earnings History by Quarter for Macrocure Ltd (NASDAQ MCUR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Macrocure Ltd (NASDAQ:MCUR)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS
Dividend History for Macrocure Ltd (NASDAQ:MCUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Macrocure Ltd (NASDAQ:MCUR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Macrocure Ltd (NASDAQ:MCUR)
Latest Headlines for Macrocure Ltd (NASDAQ:MCUR)
Macrocure Ltd (MCUR) Chart for Tuesday, October, 17, 2017